Nat Genet:林东昕院士揭示抑制胰腺癌lincRNA---LINC00673作用机制

2016-05-28 MedSci MedSci原创

中国医学科学院北京协和医学院的研究人员在新研究中揭示,在基因间长链非编码RNA (lincRNA) LINC00673中的一个胰腺癌风险变异为miR-1231构建了一个结合位点,干扰了PTPN11降解。这一重要的研究发现发布在5月23日的《自然遗传学》(Nature Genetics)杂志上。中国医学科学院的林东昕(Dongxin Lin)院士以及吴晨(Ch

中国医学科学院北京协和医学院的研究人员在新研究中揭示,在基因间长链非编码RNA (lincRNA) LINC00673中的一个胰腺癌风险变异为miR-1231构建了一个结合位点,干扰了PTPN11降解。这一重要的研究发现发布在5月23日的《自然遗传学》(Nature Genetics)杂志上。

中国医学科学院的林东昕(Dongxin Lin)院士以及吴晨(Chen Wu)博士是这篇论文的共同通讯作者。林东昕院士的主要学术贡献包括揭示并阐明我国食管癌、胰腺癌、肺癌等肿瘤的易感基因及基因-环境交互作用、遗传变异对肿瘤放化疗疗效及预后的影响。已在Nature Genetics等期刊发表科学论文237篇。

2007年,林东昕教授领导的一个研究项目确定出了一个与患癌症风险相关的CASP8基因变异。这项研究的相关论文发表在Nature Genetics杂志上(林东昕小组《自然》子刊文章确定癌症风险基因变异)。2014年8月,林东昕教授与新乡医学院的王立东教授以及美国国立卫生研究院的Philip R Taylor合作,针对3项中国人群食管鳞状细胞癌(ESCC)全基因组关联(GWAS)研究进行了联合分析,结果发表在Nature Genetics杂志上(林东昕院士等Nature子刊发表癌症GWAS研究新成果 )。2014年9月,林东昕院士以及吴晨博士领导研究人员,通过基因组关联研究鉴别出了中国人群喉鳞状细胞(LSCC)的三个易感位点。相关论文再度发表在Nature Genetics杂志上(林东昕院士Nature子刊再发GWAS研究新成果)。

在过去的十年里,科学家们已发布了1300多项全基因组关联研究(GWAS),发现了近6,500个与疾病或性状相关的基因位点。然而,其中只有7%的位点定位在蛋白质编码区域,而剩余的93%均定位在非编码区域。蛋白质编码区域的种系突变常常是极其有害或致命的,不可能让携带者生存至癌症发生;而调控区域的突变可以细胞类型或组织特异性方式造成基因表达的微小变化,有可能在携带者的预期生命期限内赋予了癌症易感性。

LincRNAs是一类长度大于200 nt的非编码转录物,是人类非编码转录组中最大的子类。越来越多的证据表明,lincRNAs参与了广泛的细胞过程,包括调控表观遗传标记和基因表达,及胚胎干细胞多能性的维持及分化。与lincRNAs具有广泛生物学作用相一致,一些研究表明包括癌症在内的许多人类疾病与lincRNAs表达和功能异常有关联。

GWAS鉴别的许多位点都定位在lincRNAs编码区域,表明lincRNAs遗传变异有可能在癌症等疾病的易感性方面起重要作用。因此,发现这样的位点及阐明它们的生物学功能,对于认识癌症的病因学,推动开发出筛查、预防和治疗癌症的新方法具有重要的意义。

在这篇新文章中,研究人员采用全基因组关联分析和功能分析,鉴别出了基因间长链非编码RNA (lincRNA) LINC00673是一个潜在的肿瘤抑制子,它的种系变异与胰腺癌风险相关。LINC00673能够增强PTPN11与E3泛素连接酶PRPF19之间的互作,通过泛素化作用促进PTPN11降解,减少SRC–ERK致癌信号,促进激活STAT1依赖性的抗肿瘤反应。LINC00673 4号外显子rs11655237处发生G>A改变为miR-1231结合构建了一个靶位点,可以一种等位基因特异性方式减小LINC00673的影响,由此赋予对肿瘤形成的易感性。

这些研究结果阐明了LINC00673在维持细胞稳态中所起的重要作用,以及它的种系变异赋予胰腺癌易感性的分子机制。

原始出处:

Zheng J, Huang X, Tan W, Yu D, Du Z, Chang J, Wei L, Han Y, Wang C, Che X, Zhou Y, Miao X, Jiang G, Yu X, Yang X, Cao G, Zuo C, Li Z, Wang C, Cheung ST, Jia Y, Zheng X, Shen H, Wu C, Lin D. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation.Nat Genet. 2016 May 23. doi: 10.1038/ng.3568

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881076, encodeId=a3f518810e605, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 16 17:10:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733779, encodeId=e4c61e33779ff, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jan 07 00:10:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686021, encodeId=1a221686021f7, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Feb 06 11:10:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048710, encodeId=864a2048e1077, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jul 06 06:10:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005623, encodeId=16b4200562318, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 09 11:10:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085090, encodeId=42d42085090c8, content=<a href='/topic/show?id=64361090564' target=_blank style='color:#2F92EE;'>#lincRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10905, encryptionId=64361090564, topicName=lincRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Dec 23 15:10:00 CST 2016, time=2016-12-23, status=1, ipAttribution=)]
    2016-08-16 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881076, encodeId=a3f518810e605, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 16 17:10:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733779, encodeId=e4c61e33779ff, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jan 07 00:10:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686021, encodeId=1a221686021f7, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Feb 06 11:10:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048710, encodeId=864a2048e1077, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jul 06 06:10:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005623, encodeId=16b4200562318, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 09 11:10:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085090, encodeId=42d42085090c8, content=<a href='/topic/show?id=64361090564' target=_blank style='color:#2F92EE;'>#lincRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10905, encryptionId=64361090564, topicName=lincRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Dec 23 15:10:00 CST 2016, time=2016-12-23, status=1, ipAttribution=)]
    2017-01-07 canlab
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881076, encodeId=a3f518810e605, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 16 17:10:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733779, encodeId=e4c61e33779ff, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jan 07 00:10:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686021, encodeId=1a221686021f7, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Feb 06 11:10:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048710, encodeId=864a2048e1077, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jul 06 06:10:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005623, encodeId=16b4200562318, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 09 11:10:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085090, encodeId=42d42085090c8, content=<a href='/topic/show?id=64361090564' target=_blank style='color:#2F92EE;'>#lincRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10905, encryptionId=64361090564, topicName=lincRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Dec 23 15:10:00 CST 2016, time=2016-12-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1881076, encodeId=a3f518810e605, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 16 17:10:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733779, encodeId=e4c61e33779ff, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jan 07 00:10:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686021, encodeId=1a221686021f7, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Feb 06 11:10:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048710, encodeId=864a2048e1077, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jul 06 06:10:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005623, encodeId=16b4200562318, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 09 11:10:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085090, encodeId=42d42085090c8, content=<a href='/topic/show?id=64361090564' target=_blank style='color:#2F92EE;'>#lincRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10905, encryptionId=64361090564, topicName=lincRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Dec 23 15:10:00 CST 2016, time=2016-12-23, status=1, ipAttribution=)]
    2016-07-06 cy0324
  5. [GetPortalCommentsPageByObjectIdResponse(id=1881076, encodeId=a3f518810e605, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 16 17:10:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733779, encodeId=e4c61e33779ff, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jan 07 00:10:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686021, encodeId=1a221686021f7, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Feb 06 11:10:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048710, encodeId=864a2048e1077, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jul 06 06:10:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005623, encodeId=16b4200562318, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 09 11:10:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085090, encodeId=42d42085090c8, content=<a href='/topic/show?id=64361090564' target=_blank style='color:#2F92EE;'>#lincRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10905, encryptionId=64361090564, topicName=lincRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Dec 23 15:10:00 CST 2016, time=2016-12-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1881076, encodeId=a3f518810e605, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 16 17:10:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733779, encodeId=e4c61e33779ff, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jan 07 00:10:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686021, encodeId=1a221686021f7, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Feb 06 11:10:00 CST 2017, time=2017-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048710, encodeId=864a2048e1077, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jul 06 06:10:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005623, encodeId=16b4200562318, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 09 11:10:00 CST 2017, time=2017-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085090, encodeId=42d42085090c8, content=<a href='/topic/show?id=64361090564' target=_blank style='color:#2F92EE;'>#lincRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10905, encryptionId=64361090564, topicName=lincRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Dec 23 15:10:00 CST 2016, time=2016-12-23, status=1, ipAttribution=)]
    2016-12-23 zutt

相关资讯

全球首例:中山医院成功完成“CT导引下胰腺射频消融导管治疗胰腺癌”

5月10日下午,中山医院介入科专家成功完成全球首例“CT导引下胰腺射频消融导管治疗胰腺癌”。在王小林教授的指导下,陈颐副主任医师带领杨敏捷、高珊珊医师,借助CT精确定位,将直径0.3毫米的Habib射频消融导管在纤细的穿刺针的帮助下,穿刺进入胰腺肿瘤不同部位,进行射频消融治疗。  毫米直径——肿瘤消融治疗器械最“苗条”的导管,仅仅相当于3、4根头发丝的粗细!

Cell:胰腺癌的潜在治疗靶标Lin28b被发现

-在一项新的研究中,来自美国麻省总医院(MGH)等机构的研究人员鉴定出一种最为常见的被称作胰腺导管腺癌(pancreatic ductal adenocarcinoma, PDAC)的胰腺癌类型的首个潜在的分子治疗靶标。除了发现在大约30%的PDAC病例中肿瘤抑制蛋白SIRT6失活之外,研究人员还鉴定出SIRT6抑制PDAC发展的精确分子机制,这一机制不同于它抑制结直肠癌的方式。相关研究结果于

Pathology:维生素A或可有效改善胰腺癌的化疗效果

在英国,每年约有8800人被诊断出胰腺癌。胰腺癌是美国最为罪名的癌症,存活率不足3%。单纯化疗和放疗往往无法治愈,手术切除则是最佳的治疗方法,大部分患者在癌细胞已发生转移时才确诊。因此,亟需一种不同的不同的治疗方法来更有效地治疗胰腺癌。原始出处:Vitamin A may help improve pancreatic cancer chemotherapy.AAAS and EurekAlert

Oncogene:“绑架”胆固醇 让胰腺癌细胞无处可逃

控制胰腺癌细胞内的胆固醇代谢就能够抑制癌细胞转移,这表明之前用于治疗动脉粥样硬化的治疗药物或将有新用途。 普渡大学的华人科学家Ji-Xin Cheng表示:“我们首次证明如果能够控制胆固醇代谢就可以抑制胰腺癌向其他器官的转移。胰腺癌是所有癌症类型中最具侵袭性的一种,因此我们选择以胰腺癌为研究对象对该方法进行检测。” Ji-Xin Cheng早先带领研究团队发现前列腺癌的侵袭性与细胞内胆固

Cell:首次鉴定出胰腺癌的潜在治疗靶标

发现肿瘤抑制蛋白SIRT6在约30%的胰腺导管腺癌(PDAC)中失活,该研究小组确定了SIRT6抑制PDAC形成的确切信号通路,这一机制不同于它抑制大肠癌的途径。该研究论文在线发布在《细胞》(Cell)杂志上。

微型药物输送设备能够大幅提高胰腺癌治疗效果

(图片摘自www.sciencealert.com) 研究者们开发出了一款用于治疗胰腺癌的小型植入型设备,通过在小鼠水平进行研究,他们发现该设备比常规的化学治疗方法更加高效,该设备将会改变胰腺癌的治疗方向。 如何将药物准确地运输到胰腺病灶一直是治疗胰腺癌的主要问题之一,作为最难治疗、同时致死率最高的癌症之一,找到更佳的治疗方案意义重大。 来自MIT的研究者们过去三年时间一直致力于研究这一